**Core tip:** Cardiovascular magnetic resonance (CMR) imaging uniquely characterizes myocardial and microvascular injury in acute myocardial infarction (AMI). Contrast-enhanced CMR offers robust, validated and reproducible surrogate markers, providing an accurate representation of pathophysiology, assessment of myocardial function and injury, and predictive value for medium to long-term LV function, remodelling and prognosis following primary percutaneous coronary intervention for STEMI. These qualities significantly increase the statistical power of studies using CMR endpoints and has resulted in an exponential increase in AMI studies utilizing CMR based endpoints. An understanding of the role of CMR in the assessment of outcomes in AMI is of key importance not only to interventional and imaging cardiologists, but to the cardiology community as a whole.

INTRODUCTION
============

Cardiovascular magnetic resonance (CMR) imaging uniquely characterises myocardial and microvascular injury in acute myocardial infarction (AMI), providing powerful surrogate markers of outcomes. The last 10 years have seen an exponential increase in studies utilising CMR based endpoints in patients with AMI undergoing primary percutaneous intervention. This article provides a contemporary, comprehensive review of the powerful role of CMR imaging in the assessment of outcomes in AMI. The theory, assessment techniques, chronology, importance in predicting left ventricular function and remodelling, and prognostic value of each CMR surrogate marker is described in detail. Major studies illustrating the importance of the markers are summarised, providing an up to date review of the literature base in CMR imaging in AMI.

MARKERS OF OUTCOMES FOLLOWING PRIMARY PERCUTANEOUS CORONARY INTERVENTION IN AMI
===============================================================================

Prognostic studies using clinical outcomes, in particular mortality require large sample sizes. Surrogate biomarkers of outcome are directly measured alternative endpoints used as a substitute for biological processes and clinical outcomes\[[@B1],[@B2]\]. CMR imaging uniquely characterises myocardial and microvascular injury in AMI due to its accuracy, reliability and validity (Figure [1](#F1){ref-type="fig"})\[[@B2]-[@B4]\]. This significantly increases the statistical power of studies, allowing sample size requirements to be reduced. CMR data are strong surrogate markers of outcome following primary percutaneous coronary intervention (PPCI) in acute ST-segment elevation MI.

![Cardiovascular magnetic resonance markers are ideal surrogate biomarkers for the assessment of revascularisation in acute myocardial infarction\[[@B2]-[@B4]\]. CMR: Cardiovascular magnetic resonance; AMI: Acute myocardial infarction; LGE: Late gadolinium enhancement.](WJC-9-109-g001){#F1}

LV EJECTION FRACTION AND VOLUMES IN AMI
=======================================

Background
----------

In the medium-term following STEMI, LV end-diastolic volume (LVEDV) increases, LV end-systolic volume (LVESV) decreases\[[@B5]-[@B7]\] and there can be compensatory hypertrophy of remote myocardium\[[@B8],[@B9]\] in order to preserve stroke volume and ejection fraction (LVEF). Adverse remodelling results from an inability of the heart to maintain geometry post MI in the context of large infarcts and increased wall stresses\[[@B10],[@B11]\]. An increase in LVEDVI \> 20%\[[@B12],[@B13]\] and increase in LVESVI \> 15%\[[@B14]\] at follow-up are the most commonly used criteria for adverse remodelling.

CMR assessment of LV volumes and ejection fraction
--------------------------------------------------

CMR is the gold standard modality for the assessment of ventricular function and volumes. It has higher spatial resolution than single-photon emission computed tomography (SPECT) (approximately 1.8 mm × 1.8 mm × 8 mm *vs* 10 mm × 10 mm × 10 mm)\[[@B15]\], and suffers from little subjectivity or reliance on patient body habitus\[[@B16]\].

Volumes and mass are assessed on analysis of a 3D cine stack of short-axis biventricular contiguous slices. Modern cine sequences use breath-hold, electrocardiographic-gated, segmented steady-state free precession (SSFP) to produce high spatial resolution images with excellent myocardium-blood contrast. Regional systolic function can alternatively be assessed using wall motion scoring\[[@B17]\].

CMR studies have demonstrated that recovery of LVEF occurs relatively early post STEMI. Ripa showed that improvement in LVEF and systolic wall thickening occurred by 1 mo, with no further change at 6 mo\[[@B5]\]. The majority of improvement in LVEF occurred between day 2 and 1 wk in the study by Mather\[[@B18]\], with a final increase by 3 mo. Beek showed that 55% of segments with initially impaired systolic wall thickness improved at 13-wk\[[@B19]\]. Ganame et al\[[@B20]\] and Dall'Armelina et al\[[@B21]\] however showed that LVEF underwent no significant change by 6 and 12 mo post PPCI respectively. This may be because their subjects sustained less myocardial damage, represented by relatively preserved LVEF and thus lower potential for improvement\[[@B21]\].

Volumetric changes occur more slowly. Ripa et al\[[@B5]\] showed a continued increase in LVEDV and reduction in LVESV until 6 mo. Engblom et al\[[@B7]\] demonstrated similar sequelae to 12-mo. Ganame showed progressive significant changes in LVEDV and LVESV and resulting LV sphericity at all timepoints to 12 mo\[[@B20]\]. These studies have important implications for optimising timing of follow-up CMR studies assessing remodelling.

The degree of impairment of LVEF and changes in volume depend on a number of CMR-based markers including infarct size (IS)\[[@B22]\], microvascular obstruction (MVO)\[[@B23],[@B24]\], intramyocardial haemorrhage (IMH)\[[@B25]\] and myocardial salvage \[non-infarcted proportion of ischaemic area at risk (AAR)\]\[[@B26],[@B27]\]. Anterior STEMI results in larger IS and lower LVEF due to the greater ischaemic AAR\[[@B28]\].

Prognostic importance of LVEF and volumes in AMI
------------------------------------------------

Norris et al\[[@B29]\] and White et al\[[@B30]\] first illustrated the prognostic importance of LVEF (strongest independent predictor of survival at 3.5 years) and LVESV (only independent predictor of long-term mortality at 6 years) respectively, using invasive ventriculography. Burns first demonstrated the prognostic importance of LVEF and LV volumes and their strong correlation with each other, using radionucletide analysis\[[@B31]\].

A large evidence base has emerged for the prognostic impact of impaired systolic function based on reduced CMR-derived LVEF (Table [1](#T1){ref-type="table"}).

###### 

Cardiovascular magnetic resonance studies illustrating the prognostic importance of left ventricular ejection fraction in acute myocardial infarction

  **Ref**.                  **Year**   ***n***   **CMR time**   **Main findings**                                                                                         **Follow-up**
  ------------------------- ---------- --------- -------------- --------------------------------------------------------------------------------------------------------- ---------------
  El Aidi et al\[[@B32]\]   2014       25497     N/A            Meta analysis of prognostic value of CMR surrogate markers. LVEF was only IP for MACE (HR 1.05 per -5%)   N/A
  Husser et al\[[@B33]\]    2012       304       7 d            LVEF was IP for MACE (HR 0.95 for each +1% LVEF)                                                          140 wk
  Eitel et al\[[@B34]\]     2011       208       3 d            LVEF was IP for MACE (HR 0.95 for each +1% LVEF)                                                          18.5 mo
  Amabile et al\[[@B35]\]   2010       114       6 d            LVEF was IP for MACE (HR 0.96 for each +1% LVEF)                                                          12 mo
  de Waha et al\[[@B36]\]   2010       438       3 d            LVEF was IP for MACE (OR 1.63) and all-cause mortality (OR 2.51)                                          19 mo
  Cochet et al\[[@B37]\]    2009       127       3-7 d          LVEF of \< 40% was IP for MACE (OR 1.20)                                                                  12 mo
  Hombach et al\[[@B6]\]    2005       110       6 d            LVEF was IP for 9 mo MACE (*P* = 0.006)                                                                   225 d

CMR time: Mean/median time of CMR post acute STEMI; MACE: Major adverse cardiovascular events; IP: Independent predictor; LVEF: Left ventricular ejection fraction; CMR: Cardiovascular magnetic resonance; N/A: Not available.

In addition to LVEF-based global systolic function, Bodi demonstrated that the number of dysfunctional segments on CMR at 1-wk post STEMI was an independent predictor of combined MACE at a median follow-up of 553 d\[[@B38]\]. The evidence base for the prognostic importance of LV volumes is largely historical, based on large echocardiographic and radionucleotide studies, demonstrating the negative prognostic impact of ventricular dilatation and remodelling as summarised in Table [2](#T2){ref-type="table"}.

###### 

Studies illustrating the prognostic importance of left ventricular volumes and adverse left ventricular remodelling in acute myocardial infarction

  **Ref**.                         **Year**   ***n***   **Modality**   **Main findings**                                                                                                                                                                           **Follow-up**
  -------------------------------- ---------- --------- -------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------
  Ahn et al\[[@B13]\]              2013       135       Echo           Adverse LV remodelling (\> 20% inc. LVEDV) at 6 mo was IP 3 yr MACE. MACE rate approximately 25% in patients with adverse LV remodelling *vs* approximately 6% in non-remodelled patients   981 d
  Hombach et al\[[@B6]\]           2005       110       CMR            Baseline LVEDV was IP for MACE (*P* = 0.038)                                                                                                                                                225 d
  St John Sutton et al\[[@B39]\]   2003       512       Echo           Percentage change in LV area (surrogate for LV volume) between baseline echo and follow-up at 12 mo was IP for ventricular ectopy and VT                                                    24 mo
  Bolognese et al\[[@B12]\]        2002       284       Echo           Baseline LVESV was IP for cardiac death and MACE. Components of MACE higher in patients with adverse remodelling (\> 20% inc. LVEDV: Mortality 14% *vs* 5%, MACE 18% *vs* 10%)              5 yr
  Otterstad et al\[[@B40]\]        2001       712       Echo           Increase in LVESV between acute scan at 7 d and echo at 3 mo strongest IP for MACE                                                                                                          24 mo
  St John Sutton et al\[[@B41]\]   1994       512       Echo           LV end-diastolic area (RR 1.1) and LV end-systolic area (RR 1.1) on baseline echo, and %-change in LV area at 12 mo echo (RR 1.55) were strongest IPs for MACE                              12 mo
  White et al\[[@B30]\]            1987       605       LV gram        LVESV of LV gram at 4 wk was strongest IP of long-term mortality (*P* \< 0.0001)                                                                                                            78 mo

MACE: Major adverse cardiovascular events; IP: Independent predictor; LVEDV: Left ventricular end-diastolic volume; LVESV: Left ventricular end-systolic volume; Modality: Modality of LV volume assessment (CMR: Cardiovascular MRI; Echo: Echocardiography; LV gram: LV contrast angiography).

Negative LV remodelling has demonstrated prognostic importance in two studies, based on the cut-off of LVEDVI dilation of \> 20% at 6-mo follow-up\[[@B12],[@B13]\].

Recently, left ventricular global performance index has been proposed as a CMR marker of cardiac performance, incorporating LVEF, LV volumes and mass. It has been assessed in one study in STEMI and correlated strongly with IS, MSI, MVO and IMH extent, and had incremental prognostic value to LVEF in predicting 12-mo MACE\[[@B42]\]. Further work is needed to investigate its prognostic value in STEMI.

MYOCARDIAL STRAIN IN AMI
========================

CMR-measured myocardial strain (tissue deformity) is the gold standard non-invasive measure of systolic and diastolic myocardial function\[[@B43]\]. Circumferential strain (Ecc) describes shortening of fibres (contraction) in a short-axis plane tangential to the epicardium; longitudinal strain (Ell) describes shortening in the long axis, and radial strain (Err) describes lengthening (thickening) of fibres towards the centre of the ventricle. Torsion is wringing of the ventricle caused by clockwise rotation at the base, and anticlockwise at the apex.

Strain offers greater accuracy in detecting myocardial dysfunction compared with global (LVEF) and regional (visual wall-motion scoring, segmental wall thickening)\[[@B44]\] measures.

CMR assessment of myocardial strain
-----------------------------------

In 1989, Axel et al\[[@B45]\] developed a T1 spoiled gradient echo sequence, creating "tags" formed by saturation of thin myocardial lines running in perpendicular directions in-plane to form a myocardial grid. These lines act as tissue markers, tracking myocardial deformation as shown in Figure [2](#F2){ref-type="fig"}. Peak systolic strain and peak diastolic strain rate (relaxation rate of strain) provide very sensitive measures of systolic and diastolic function respectively. Its accuracy has been validated on comparison with sonomicrometry\[[@B46],[@B47]\]. Harmonic Phase Analysis (HARP) is currently the most widely used CMR strain method\[[@B48]\].

![Cardiovascular magnetic resonance assessment of strain using tissue tagging. Cine SSFP images in end-diastole (A) and end-systole (C), with corresponding Spatial Modulation of Motion (SPAMM) tagged images (B and D). Grid lines (tags) are visible and contours drawn at 3 myocardial levels \[green (epicardial), red (mid myocardial), yellow (endocardial)\] allow tracking of myocardial motion and strain (circumferential), here using Harmonic Phase Analysis.](WJC-9-109-g002){#F2}

Feature tracking (FT) has been introduced as an alternative method to tagging for assessing strain on CMR. FT tracks anatomical features of interest along contour lines on routinely acquired SSFP cine images analogous to echocardiographic Speckle Tracking, obviating the need for additional tagging sequences\[[@B49]\]. FT-derived strain has been compared to tagging in acute STEMI and shown greater feasibility, accuracy and observer agreement\[[@B50]\] and remains an exciting prospect.

CMR LV strain as a predictor of LV function and remodelling in AMI
------------------------------------------------------------------

Strain could improve our understanding of the mechanics underlying LV dysfunction associated with prognostic CMR surrogate markers of myocardial damage in STEMI (*e.g*., MVO, IMH, oedema).

Systolic function is also in remote (non-infarcted) segments, and LV mechanics outside of the infarct zone are also affected during infarction and contribute to remodelling\[[@B44],[@B51],[@B52]\]. MVO had the highest predictive value for persistent dysfunction on circumferential strain at 7-mo post STEMI and may result in systolic dysfunction due to direct mechanical effects (myocardial stiffness)\[[@B53]\]. Baseline segmental circumferential strain was the strongest predictor of segmental functional recovery at 3-mo in a model containing infarct transmurality and MVO\[[@B54]\]. FT-derived global circumferential strain assessed acutely post PPCI was recently shown to correlated strongly with acute IS on late gadolinium enhancement (LGE) imaging (r = 0.75) and final LVEF at 6 mo (r = -0.71). Global circumferential strain was a stronger predictor of functional recovery (LVEF \> 50%) at 6 mo than global longitudinal strain, age, diabetes and baseline LVEF, and was of similar predictive value to acute IS \[AUC 0.86 (Ecc) *vs* 0.92 (IS)\]\[[@B55]\].

Prognostic importance of LV strain in AMI
-----------------------------------------

The evidence base for the prognostic importance of LV strain post STEMI is currently based on echocardiographic studies demonstrating that global longitudinal predicts medium and long-term using Speckle Tracking analysis as summarised in Table [3](#T3){ref-type="table"}.

###### 

Studies illustrating the prognostic importance of left ventricular strain in acute myocardial infarction

  **Ref**.                  **Year**   ***n***   **Modality**   **Main findings**                                                                                      **Follow-up**
  ------------------------- ---------- --------- -------------- ------------------------------------------------------------------------------------------------------ ---------------
  Ersbøll et al\[[@B56]\]   2014       1048      TTE            (E-prime divided by peak early diastolic strain rate) strongest IP of MACE and death                   29 mo
  Ersbøll et al\[[@B57]\]   2013       849       TTE            GLS was IP of MACE                                                                                     30 mo
  Hung et al\[[@B58]\]      2010       610       TTE            GLS and strain-rate, and GCS and strain-rate IPs for MACE in model with WMS, LVEF                      25 mo
  Antoni et al\[[@B59]\]    2010       659       TTE            GLS (HR 1.2) was IP of mortality. LVEF, wall-motion score and Tissue Doppler mitral valve inflow not   21 mo

TTE: Transthoracic echocardiography; GLS: Global longitudinal strain; MACE: Major adverse cardiovascular events; IP: Independent predictor; HR: Hazard ratio; LVEF: Left ventricular ejection fraction.

INFARCT SIZE IN AMI
===================

Background
----------

The "ischaemic cascade" is the sequence of pathophysiological effects developing immediately following coronary occlusion. Aerobic respiration loses efficiency resulting in cellular oedema. With increasing ischaemic time, cell membranes rupture. Following healing, necrotic cells are replaced by extracellular collagen deposition (scar). The acute and chronic phases are characterised by increased myocardial extracellular volume\[[@B60]-[@B62]\].

CMR assessment of IS in AMI
---------------------------

Gadolinium contrast agents are large extracellular molecules (Figure [3](#F3){ref-type="fig"}). Infarct can be visualised on T1-weighted imaging approximately 10 min after intravenous contrast administration, known as LGE imaging.

![Mechanism of late gadolinium enhancement. Gadolinium is extracellular. A: In normal myocardium, gadolinium washes out approximately 10 min post administration and there is no late gadolinium enhancement (LGE); B: In acute infarct, gadolinium (yellow stars) enters ruptured cell membranes and causes LGE; C: In chronic infarct, LGE results from increased extracellular space due to fibrotic scar deposition.](WJC-9-109-g003){#F3}

In acute infarct, LGE results from gadolinium entering ruptured cell membranes. In chronic infarction, LGE results from increased extracellular space due to collagen deposition and prolonged washout due to reduced capillary density within myocardium\[[@B60],[@B63]\]. Gadolinium shortens T1, causing infarcted myocardium to appear bright, and normal myocardium to appears black (Figure [4](#F4){ref-type="fig"})\[[@B63],[@B64]\]. Normal myocardium is progressively nulled using the appropriate inversion time to provide optimal contrast between infarct and normal myocardium.

![Late gadolinium enhancement of acute infarct. Infarct appears white (enhanced) in the inferior wall, with unaffected myocardium black (nulled). A: 2-chamber long-axis view; B: Short-axis view, mid ventricular level. The posteromedial papillary muscle is also infarcted in the short-axis view.](WJC-9-109-g004){#F4}

Typically, a high spatial resolution of approximately 1.4 mm × 1.6 mm × 6-8 mm is achieved\[[@B15]\]. IS is typically expressed as a percentage of total LV mass. Delineation of infarct can be performed visually (manual quantification)\[[@B6],[@B9],[@B22]\], however most groups use semi-automated methods to reduce observer variability. These include enhancing myocardium exceeding a pre-defined signal intensity (SI) threshold, typically \> 2-6 standard deviations above that of remote (non-infarcted) myocardium\[[@B2],[@B65]\]. Currently, the semi-automated full-width at half-maximum (FWHM) method is commonly used\[[@B66]-[@B70]\], defining infarct as myocardium with SI \> 50% of the peak SI in the infarct core. Amado demonstrated that FWHM had the highest interobserver agreement and closest correlation with TTC-stained infarct in a dog model of acute infarction (r^2^ = 0.94), compared with standard deviation methods\[[@B66]\]. This may be because FWHM is less prone to IS overestimation in the presence of oedema, and partial volume effects giving rise to intermediate signal intensities\[[@B18],[@B71]\]. Comparing techniques in STEMI patients showed that FWHM quantification had the lowest intraobserver and interobserver variability, and greatest agreement with LVEF\[[@B72]\].

CMR measurement of IS on LGE is well validated\[[@B63],[@B64]\]. Kim demonstrated that IS in dog myocardium on *ex-vivo* CMR corresponded closely with IS derived from tetrazolium (TTC) staining (r = 0.99)\[[@B15],[@B64]\]. LGE has higher sensitivity for infarct detection compared with SPECT. In an experimental model of MI, CMR LGE detected 92% of all segments with subendocardial infarction (\< 50% transmurality) compared with only 28% with SPECT\[[@B15]\]. In patients with MI, SPECT only detects approximately 50% of the infarcts seen on LGE. The superior sensitivity is due to the increased spatial resolution and reproducibility of CMR\[[@B60]\].

Since gadolinium is distributed throughout the extracellular space, gadolinium contrast agents are not specific to necrosis. Acutely, the area of LGE detects not only necrotic cells but also the increased (oedematous) interstitium surrouding viable cells, and thus can overestimate true IS. Studies of IS chronology in humans corroborate this (Table [4](#T4){ref-type="table"}). Indeed, severely dysfunctional segments with minimal myocardial salvage early post STEMI can show significant functional improvement at follow-up\[[@B73]\].

###### 

Temporal changes in cardiovascular magnetic resonance-derived infarct size in acute myocardial infarction

  **Ref**.                        **Year**   ***n***   **CMR times post STEMI**   **Relative LGE IS reduction**   **LGE method**   **Main findings**
  ------------------------------- ---------- --------- -------------------------- ------------------------------- ---------------- ------------------------------------------------------------------------------------
  Carrick et al\[[@B74]\]         2016       30        8 h → 3 d → 10 d → 7 mo    26%                             Automated        Significant decrease d3 to d10 (20% ± 13% to 14% ± 10% LV mass). No change at 7 mo
  Dall'Armelina et al\[[@B21]\]   2011       30        2 d → 6 mo                 22%                             \> 2SD           IS reduced at times from 27% ± 15% LV mass 24 h post PPCI, to 21% ± 11% at 6 mo
  Mather et al\[[@B18]\]          2011       48        2 d → 1 wk → 30 d → 3 mo   37%                             \> 2SD           27% IS drop between d2 and d7 post PPCI, no change at 3 mo
  Ganame et al\[[@B20]\]          2011       58        3 d → 4 mo → 12 mo         45%                             Manual           33% decrease IS d3 and 4 mo then no further decrease at 12 mo
  Ibrahim et al\[[@B9]\]          2010       17        1 d → 1 wk → 1 mo → 6 mo   37%                             Manual           34% reduction in IS from d2 to 1 wk, then no further change at 1 and 6 mo
  Engblom et al\[[@B7]\]          2009       22        1 d → 1 wk → 12 mo         40%                             Automated        28% reduction in IS between d1 and 1 wk
  Ripa et al\[[@B5]\]             2007       58        2 d → 1 mo → 6 mo          30%                             Manual           14% % reduction in IS from d2 to 1 mo
  Hombach et al\[[@B6]\]          2005       110       6 d → 9 mo                 28%                             Manual           28% reduction in IS from d6 to 9 mo

LGE method: SD: Standard deviations; Total LGE IS Overest: Relative overestimation of final IS (last timepoint) on acute CMR; CMR: Cardiovascular magnetic resonance; LGE: Late gadolinium enhancement; IS: Infarct size; PPCI: Primary percutaneous coronary intervention.

The majority of IS reduction occurs relatively early post STEMI, particularly by 1 wk. Indeed IS assessed at 1 wk has been shown to closely correlate with final IS\[[@B7],[@B9],[@B18]\]. Overestimation of necrosis by LGE-derived IS early post STEMI is due to a combination of oedema, infarct resorption and partial volume effects. Oedema results in an overestimation of LGE IS due to increased extracellular water content and thus volume of distribution of contrast agent\[[@B66],[@B75]\].

Infarct resorption results from the healing process where collagenous scar tissue is produced to provide stability and tensile strength to necrotic myocardium\[[@B7],[@B11]\]. This was confirmed in a canine model where a 3.4-fold decrease in infarct volume was seen between day 3 and 8-wk post infarct on *ex-vivo* LGE and TTC-stained slices\[[@B64]\]. The degree of infarct resorption has been shown to be proportional to initial IS (r = 0.65) and presence of LV remodelling (r = 0.41)\[[@B10]\]. The greater degree of infarct resorption relative to total myocardial mass and volume results in an inability to maintain LV geometry in light of mechanical stresses post STEMI, resulting in adverse LV remodelling and sphericity\[[@B10],[@B76]\].

Factors known to affect IS include AAR extent\[[@B77]-[@B79]\]; collateral flow to the AAR\[[@B79],[@B80]\]; MVO\[[@B81]\]; time to reperfusion\[[@B82]\] and hyperglycaemia\[[@B83]\].

CMR IS as a predictor of LV function and remodelling in AMI
-----------------------------------------------------------

**Segmental function:** Kim illustrated in stable patients awaiting revascularisation, that LGE transmurality strongly predicted recovery of systolic function in dysfunctional segments. Only 2% of segments with \> 75% transmurality improved after revascularisation\[[@B84]\]. Segmental extent of LGE has also been shown to negatively predict functional recovery in dysfunctional segments following PPCI for acute STEMI, as summarised in Table [5](#T5){ref-type="table"}.

###### 

Cardiovascular magnetic resonance studies illustrating importance of segmental late gadolinium enhancement extent and functional recovery in acute myocardial infarction

  **Ref**.                   **Year**   ***n***   **LGE method**   **Cutoff (LGE)**   **Main findings**                                                                                                                                      **Time of CMR 1**   **Time of CMR 2**
  -------------------------- ---------- --------- ---------------- ------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------- -------------------
  Khan et al\[[@B85]\]       2016                 FWHM             50% SEE            SEE strong predictor or segmental functional improvement (AUC 0.840) and normalisation (AUC 0.887)                                                     2 d                 9 mo
  Wong et al\[[@B54]\]       2014       45        FWHM             50% SEE            Inverse relationship between TEE and likelihood of functional recovery on WMS at 24 wk (area under curve 0.68)                                         8 d                 13 wk
  Natale et al\[[@B86]\]     2011       46        2SD              50% TEE            Inverse relationship TEE and likelihood of functional recovery on SWT (93% sens, 75% spec)                                                             5 d                 20 wk
  Engblom et al\[[@B7]\]     2008       22        Manual           50% TEE            Inverse relationship between TEE and functional recovery on WMS                                                                                        7 d                 24 wk
  Shapiro et al\[[@B87]\]    2007       17        Manual           50% SEE            Inverse relationship between TEE and likelihood of functional recovery on WMS at 26 wk. Odds-ratio of functional recovery 0.2 with each SEE quartile   6 d                 26 wk
  Kitagawa et al\[[@B88]\]   2007       18        2SD              50% TEE            Inverse relationship between TEE and functional recovery. 31% segments \> 50% TEE still improved                                                       5 d                 39 wk
  Janssen et al\[[@B89]\]    2006       67        Manual           50% TEE            Inverse relationship between TEE and functional recovery on WMS at 12w (51%-75%: 39% segments improved, 76%+: 21% improved)                            4 d                 12 wk
  Motoyasu et al\[[@B90]\]   2004       23        2SD              50% TEE            Inverse relationship between SEE and functional recovery on SWT                                                                                        25 d                24 wk
  Beek et al\[[@B19]\]       2003       30        6SD              50% SEE            Inverse relationship between SEE and functional recovery on WMS                                                                                        7 d                 13 wk

WMS: Wall motion scoring; SWT: Systolic wall thickening; TEE: Transmural extent of enhancement; SEE: Segmental extent of enhancement; SD: Standard deviations.

**Global function:** IS is a powerful independent predictor of global LV function and adverse LV remodelling in the medium to long-term post STEMI as summarised in Table [6](#T6){ref-type="table"}.

###### 

Cardiovascular magnetic resonance studies illustrating importance of infarct size on left ventricular function and remodelling in acute myocardial infarction

  **Ref**.                    **Year**   ***n***   **LGE method**   **Main findings**                                                                                     **Time post STEMI of predictive CMR**   **Follow-up**
  --------------------------- ---------- --------- ---------------- ----------------------------------------------------------------------------------------------------- --------------------------------------- -----------------------
  Ahn et al\[[@B13]\]         2013       135       Manual           IS strongest IP of LVR in model with LVEF and MI location                                             7 d                                     6 mo (echocardiogram)
  Husser et al\[[@B33]\]      2012       304       \> 2SD           IS IP of LVR in model incl. LVEF, IS, LV vols, MVO                                                    6 d                                     189 d
  Monmeneu et al\[[@B91]\]    2012       118       \> 2SD           No. segments \> 50% transmurality IP for LVR                                                          6 d                                     6 mo
  Ezekowicz et al\[[@B92]\]   2010       64        Manual           IS strongest IP of LVEF in model with MVO, troponins                                                  7 d                                     3 mo
  Ganame et al\[[@B25]\]      2009       98        Manual           IS strongest IP of LVR (\>\> MVO, AAR, Troponin-I)                                                    2 d                                     6 mo
  Bodi et al\[[@B93]\]        2009       214       \> 2SD           Extent of transmural necrosis (no. segments \> 50% TEE) strongest IP for LV recovery (+ \> 5% LVEF)   7 d                                     6 mo
  Wu et al\[[@B94]\]          2008       122       Manual           IS extent only IP for LVEF and LVR                                                                    2 d                                     4 mo
  Hombach et al\[[@B6]\]      2005       110       Manual           IS extent IP of LVR in model with MVO, % transmurality                                                6 d                                     225 d

IS: Infarct size; IP: Independent predictor; LVR: LV remodelling; LVEDVI: Left-ventricular end-diastolic volume index; LVEDVI: Left-ventricular end-systolic volume index; LVEF: Left ventricular ejection fraction; MVO: Microvascular obstruction; SD: Standard deviation.

Prognostic importance of CMR-derived IS in AMI
----------------------------------------------

The goal of STEMI management is early reperfusion in order to minimise IS and thus maximise myocardial salvage\[[@B95]\]. There is a strong evidence base for the prognostic importance of CMR-derived IS post STEMI, as summarised in Table [7](#T7){ref-type="table"}. IS strongly predicts medium to long-term clinical outcomes.

###### 

Cardiovascular magnetic resonance studies illustrating the prognostic importance of infarct in acute myocardial infarction

  **Ref**.                          **Year**   ***n***   **LGE method**   **Main findings**                                                                                                        **CMR timepoint**   **Follow-up**
  --------------------------------- ---------- --------- ---------------- ------------------------------------------------------------------------------------------------------------------------ ------------------- ---------------
  Husser et al\[[@B96]\]            2013       250       \> 2SD           Extent of transmural infarction (no. of segments \> 50% transmurality) only IP for MACE at 6 mo                          7 d                 163 wk
  Izquierdo et al\[[@B97]\]         2013       440       \> 2SD           IS was IP for AACEs (arrhythmic cardiac events: Sudden death, VT, VF, ICD shock) in model including LVEF, hypertension   7 d                 123 wk
  Eitel et al\[[@B34]\]             2011       208       \> 5SD           IS was IP of MACE at 19 mo in model including MVO, LVEF, MSI, Killip, TIMI post-PPCI                                     3 d                 18.5 mo
  Miszalski-Jamka et al\[[@B98]\]   2010       77        Manual           LV transmurality index IP (HR 1.03) and IS (HR 1.03) IPs for MACE in a model containing RVEF and RV IS                   "3-5 d"             1150 d
  Larose et al\[[@B67]\]            2010       103       FWHM             IS strongest IP for MACE (HR 1.36) in model containing LVEF, CK. LGE \> 23% had HR 6.1 for MACE                          4.5 h               2 yr
  Bodi et al\[[@B38]\]              2009       214       \> 2SD           Extent of transmural infarction (no. of segments \> 50% transmurality) IP for MACE (HR 1.35 if \> 5 segs)                7 d                 553 d
  Wu et al\[[@B99]\]                2008       122       Manual           IS only IP of 2 yr MACE in model containing LVEF, LVESVI                                                                 2 d                 538 d

LGE: Late gadolinium enhancement; FWHM: Full-width half-maximum; SD: Standard deviations; MACE: Major adverse cardiovascular events; LVEF: Left ventricular ejection fraction; PPCI: Primary percutaneous coronary intervention; LGE method (LGE quantification method): SD: Standard deviations; FWHM: Full-width half-maximum.

MVO IN AMI
==========

Background
----------

Despite prompt IRA recanalization, perfusion of the microcirculatory bed does not always ensue. Histopathogical studies have demonstrated that the infarct core (endocardial) perishes first as necrosis spreads transmurally towards the epicardium. This is known as the "wavefront theory"\[[@B100]\]. At the infarct core, necrosis occurs rapidly with myocardial and capillary endothelial cells perishing simultaneously. Capillaries can become obstructed by cellular debris, resulting in non-perfusion of the infarct core, despite IRA patency\[[@B101]\]. This is known as MVO and can be indicated at angiography, as "no reflow"\[[@B101]\].

CMR assessment of MVO in AMI
----------------------------

Three CMR methods demonstrate MVO (Figure [5](#F5){ref-type="fig"}). MVO extent is typically expressed as a percentage of LV mass: (1) Qualitative first-pass rest perfusion. A modified version involves quantification of myocardial blood flow (SI-time curve) and time to 50% of maximal SI\[[@B102],[@B103]\]; (2) Hypoperfusion on inversion recovery images between 1-3 min post contrast. A fixed inversion time of approximately 440 ms nulls MVO and retains intermediate signal in normal myocardium. This is known as "early MVO (E-MVO)"\[[@B28],[@B104]\]; and (3) Hypointensity within infarct core on LGE due to absence contrast perfusion, known as "late MVO (L-MVO)". L-MVO occurs in upto 60% of patients on CMR within the first week post STEMI\[[@B5],[@B6],[@B18],[@B20]\]. This is the preferred method of MVO demonstration in contemporary clinical practice and research.

![Early and late microvascular obstruction on cardiovascular magnetic resonance. A: Early gadolinium imaging at 1-min post contrast with hypoperfusion in anteroseptal, anterior and anterolateral segments, consistent with early MVO (E-MVO, \*); B: Corresponding late gadolinium image showing transmural infarction with a hypointense late MVO core (L-MVO, \*\*) co-localising with E-MVO. MVO: Microvascular obstruction.](WJC-9-109-g005){#F5}

L-MVO extent is maximal at 48 h post infarct\[[@B8],[@B18]\], and then decreases. It exists for at least 1 wk, and for up to 1 mo\[[@B8],[@B18]\] and then resolves in the medium-term in humans (Table [8](#T8){ref-type="table"}). Animal models corroborate these findings\[[@B105],[@B106]\].

###### 

Temporal changes in cardiovascular magnetic resonance late microvascular obstruction in acute myocardial infarction

  **Ref**.                  **Year**   ***n***   **CMR timepoints**         **LGE method**   **Main findings**
  ------------------------- ---------- --------- -------------------------- ---------------- --------------------------------------------------------------------------------------
  Carrick et al\[[@B74]\]   2016       30        8 h → 3 d → 10 d → 7 mo    Auto             L-MVO in 20%, peaked early at 8 h and stable at d3. Decreased by d10, absent at 7 mo
  Mather et al\[[@B18]\]    2011       48        2 d → 1 wk → 30 d → 3 mo   \> 2SD           L-MVO in 60%, peak at d2. Decrease at subsequent points. L-MVO absent at 3 mo
  Ganame et al\[[@B20]\]    2011       58        3 d → 4 mo → 12 mo         Manual           L-MVO in 64%. L-MVO absent at 4 mo
  Ripa et al\[[@B5]\]       2007       58        2 d → 6 mo                 Manual           L-MVO in 42%. L-MVO absent at 6 mo
  Hombach et al\[[@B6]\]    2005       110       6 d → 9 mo                 Manual           46% had L-MVO (2.8% LV mass, 16% of IS) on acute CMR. L-MVO absent at 6 mo

MVO: Microvascular obstruction; LGE method: SD: Standard deviations; IS: Infarct size; LV: Left ventricle; CMR: Cardiovascular magnetic resonance.

The extent of MVO on CMR has been shown to correlate with IS\[[@B82],[@B94],[@B107],[@B108]\], oedema, IMH, TIMI-flow pre PCI\[[@B35],[@B109]\] and time to reperfusion\[[@B35],[@B82],[@B110]\].

CMR MVO as a predictor of LV function and remodelling in AMI
------------------------------------------------------------

L-MVO is a strong independent predictor of medium-term LV function and adverse remodelling (Table [9](#T9){ref-type="table"}). It is likely that this is because L-MVO reflects more severe microvascular and myocardial damage than E-MVO\[[@B28],[@B36]\]. In most studies demonstrating the independent predictive value of L-MVO on LV function and remodelling, E-MVO was not a predictor\[[@B103],[@B111],[@B112]\]. L-MVO was a predictor independent of baseline IS\[[@B6],[@B20],[@B92],[@B111]-[@B113]\]. Monocyte recruitment, crucial in cellular debris removal and scar formation, is impaired in areas of L-MVO in rat myocardium and may contribute to the adverse remodelling\[[@B114]\].

###### 

Cardiovascular magnetic resonance studies illustrating the importance of late microvascular obstruction on left ventricular function and remodelling in acute myocardial infarction

  **Ref**.                    **Year**   ***n***   **LGE method**   **Main findings**                                                                                           **Time post STEMI of predictive CMR**   **Follow-up**
  --------------------------- ---------- --------- ---------------- ----------------------------------------------------------------------------------------------------------- --------------------------------------- ---------------
  Kidambi et al\[[@B115]\]    2013       39        \> 2SD           L-MVO only IP of impaired infarct strain. Model with IS, TIMI flow, diabetes, transmurality                 3 d                                     3 mo
  Wong et al\[[@B103]\]       2012       40        Manual           L-MVO extent only IP for LVEF at 3 mo in model including E-MVO, IS and myocardial blood flow on perfusion   3 d                                     3 mo
  Ezekowitz et al\[[@B92]\]   2010       64        Manual           L-MVO extent was IP of LVEF in model with IS and NT-proBNP                                                  7 d                                     4 mo
  Weir et al\[[@B112]\]       2010       100       Manual           L-MVO extent was only IP of LVR in model with TIMI post PCI, E-MVO, IS                                      4 d                                     6 mo
  Ganame et al\[[@B25]\]      2009       98        Manual           L-MVO extent was IP of LVR in model with IS, troponin-I, TTR                                                2 d                                     6 mo
  Nijveldt et al\[[@B111]\]   2008       60        Manual           L-MVO presence strongest IP of LVEF change and LVR in model with TTR, IS, LVEF, E-MVO                       5 d                                     4 mo
  Hombach et al\[[@B6]\]      2005       110       Manual           L-MVO extent IP for LVR in model with baseline IS, infarct transmurality                                    6 d                                     225 d

MVO: Microvascular obstruction; IS: Infarct size; IP: Independent predictor; TTR: Time to revascularisation; LVR: Left ventricular remodelling; LVEF: Left ventricular ejection fraction; LVEDVI: Left-ventricular end diastolic volume index; LVESVI: Left-ventricular end systolic volume index.

Prognostic importance of CMR MVO in AMI
---------------------------------------

An increasing evidence base demonstrates the strong medium-term prognostic value of L-MVO following STEMI, independent of IS and LVEF\[[@B6],[@B36],[@B37],[@B116]\] (Table [10](#T10){ref-type="table"}). The 2 studies featuring both L-MVO and E-MVO showed that L-MVO was a stronger prognostic indicator\[[@B36],[@B37]\]. Regenfus et al\[[@B117]\] demonstrated that L-MVO was the strongest IP of long-term combined MACE at 6 years follow-up in a model including CMR-assessed LVEF and IS (HR 3.9), providing incremental prognostic value over traditional CMR markers of myocardial damage. A meta-analysis\[[@B118]\] (8 studies, *n* = 1025) demonstrated that L-MVO presence was the strongest independent predictor of medium-term combined MACE (HR 3.7) and cardiovascular death (HR 13.2) at 2 years independent of IS and LV volumes.

###### 

Cardiovascular magnetic resonance studies illustrating the prognostic importance of late microvascular obstruction in acute myocardial infarction

  **Ref**.                    **Year**   ***n***   **LGE method**   **Main findings**                                                                                                                                                                                **Time of prognostic CMR post STEMI**   **Follow-up**
  --------------------------- ---------- --------- ---------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------- ---------------
  Regenfus et al\[[@B117]\]   2015       249       Manual           L-MVO extent strongest IP for MACE in model including IS, LVEF, TIMI pre and post PPCI and no. diseased vessels                                                                                  3.7 d                                   72 mo
  Eitel et al\[[@B119]\]      2014       738       \> 5SD           Largest multicentre study of L-MVO in PPCI. L-MVO \> 1.4% LVM and TIMI risk score only IPs of combined MACE. Adding L-MVO to model with clinical predictors, LVEF and IS increased c-statistic   7 d                                     6 mo
  de Waha et al\[[@B120]\]    2012       438       Manual           L-MVO extent IP for combined MACE in model including IS, LV volumes (only other IP was LVEF). L-MVO/IS strongest IP in model including L-MVO extent, LVEF, IS, LV volumes                        3 d                                     19 mo
  de Waha et al\[[@B36]\]     2010       438       Manual           Presence and extent of L-MVO were strongest IPs for MACE and mortality in models with IS, LVEF, ST-res, TIMI-flow post PCI. E-MVO was not an IP                                                  3 d                                     19 mo
  Cochet et al\[[@B37]\]      2009       184       Manual           L-MVO strongest IP for MACE, in models including GRACE score, IS, LVEF. L-MVO stronger IP than E-MVO (OR 8.7 *vs* 2.5)                                                                           "3-7 d"                                 12 mo
  Bruder et al\[[@B116]\]     2008       143       Manual           Only extent of L-MVO \> 0.5% LV mass was IP for MACE; model included IS, LVEF, age, DM, sex                                                                                                      4.5 d                                   12 mo
  Hombach et al\[[@B6]\]      2005       110       Manual           L-MVO IP for MACE (*P* = 0.04) in model including LV end-diastolic volume and LVEF                                                                                                               6 d                                     268 d

MVO: Microvascular obstruction; LVEF: Left ventricular ejection fraction; IS: Infarct size; PCI: Percutaneous coronary intervention; MACE: Major adverse cardiovascular events; IP: Independent predictor.

The strong adverse prognostic value of L-MVO may be due to its negative effects on LV function, wall thickness and stiffness, and remodelling, and subsequent risk of heart failure and arrhythmias\[[@B6],[@B20],[@B92],[@B111]-[@B113]\].

IMH IN AMI
==========

Background
----------

IMH is a reperfusion injury occurring when restored blood flow into damaged capillaries extravasates erythrocytes into myocardium\[[@B121],[@B122]\]. CMR-derived IMH was first described in reperfused canine myocardium on *ex-vivo* T2-weighted spin-echo (T2w-TSE) imaging with excellent agreement with histology (r = 0.96 for IMH extent)\[[@B123]\].

CMR assessment of IMH in AMI
----------------------------

Paramagnetic haemoglobin breakdown products shorten T2 relaxation times\[[@B123],[@B124]\]. IMH is seen as hypointense zones within hyperintense oedematous myocardium on T2w-TSE sequences. It shows good histological correlation in canine myocardium (*ex-vivo* MRI, r = 0.96)\[[@B123]\] and in an human autopsy case series (*in-vivo* MRI, r = 0.97)\[[@B124]\]. IMH occurs exclusively in areas of L-MVO (r^2^ for co-localisation approximately 0.9) (Figure [6](#F6){ref-type="fig"})\[[@B25],[@B33],[@B125],[@B126]\].

![Intramyocardial haemorrhage on cardiovascular magnetic resonance. A: T2-weighted spin-echo image with hypointensity corresponding with IMH within the hyperintense oedematous region in the inferior wall (red arrow); B: Corresponding LGE image showing co-localisation of IMH and L-MVO (yellow arrow). IMH: Intramyocardial haemorrhage; LGE: Late gadolinium enhancement; MVO: Microvascular obstruction.](WJC-9-109-g006){#F6}

Newer sequences based on direct quantification of T2 and T2\*\[[@B74],[@B126]-[@B129]\] allow IMH to be quantified without the limitations of T2w-TSE imaging. Initial studies have been promising and shown that these sequences are reproducible and appear more sensitive and accurate than T2w-TSE for IMH detection\[[@B126],[@B130],[@B131]\]. O'Regan et al\[[@B126]\] showed that T2\* had 100% sensitivity for IMH detection compared to 90% for T2w-TSE, where the "gold standard" was co-localisation with L-MVO. In canines, T2\* in haemorrhagic infarcts closely correlates with iron levels on spectrometry, and T2\*-detected IMH co-localises with iron deposition on Perl's staining\[[@B132]\] and extravasated erythrocytes on Haematoxylin-Eosin staining\[[@B128]\]. In pigs, regions of IMH on T2\* imaging showed vessel degeneration and iron deposition\[[@B8]\].

There is a paucity of data on temporal changes in CMR-detected IMH. Mather et al\[[@B18]\] showed that IMH on T2w-TSE was present in 33% of patients, with maximal extent at 48 h post PPCI and progressively resolution by 3 mo. Carrick et al\[[@B74]\] recently demonstrated that the incidence and extent of IMH on T2\* increased between 8 h and 3 d post PPCI. Its extent was significantly lower at 10 d and was seen in only 13% of patients at 7 mo. The authors also found that MVO was present in all patients with IMH, and its extent peaked earlier at 8 h suggesting that IMH is an ensuing reperfusion injury in regions of MVO.

CMR IMH as a predictor of LV function and remodelling in AMI
------------------------------------------------------------

There is a small evidence base demonstrating that IMH is a strong univariate predictor of medium-term impaired LV function and remodelling, however multivariate analysis reveals mixed results, with some studies suggesting no incremental predictive value of IMH over MVO and IS (Table [11](#T11){ref-type="table"}).

###### 

Cardiovascular magnetic resonance studies illustrating the importance of intramyocardial haemorrhage on left ventricular function and remodelling in acute myocardial infarction

  **Ref**.                   **Year**   ***n***   **IMH CMR method**   **Main findings**                                                                                                                  **CMR time post MI**   **Mean/median F/U CMR**
  -------------------------- ---------- --------- -------------------- ---------------------------------------------------------------------------------------------------------------------------------- ---------------------- -------------------------
  Carrick et al\[[@B74]\]    2016       245       T2\*                 IMH strongest IP for LVR. IMH associated with lower LVEF and greater volumes                                                       3 d                    7 mo
  Kidambi et al\[[@B115]\]   2013       39        T2w-TSE and T2\*     IMH associated with attenuation of follow-up infarct strain                                                                        3 d                    3 mo
  Husser et al\[[@B33]\]     2012       304       T2w-TSE              IMH strongest IP for LVR in model with LVEF, IS, LV vol, L-MVO                                                                     6 d                    189 d
  Mather et al\[[@B131]\]    2011       48        T2w-TSE and T2\*     IMH strongest IP of LVR in model with IS, LVEF, LVESV, E-MVO, MSI                                                                  2 d                    3 mo
  Beek et al\[[@B24]\]       2010       45        T2w-TSE              IMH was a univariate predictor of LVEF. However no prognostic significance beyond baseline LVEF and MVO in predicting final LVEF   5 d                    4 mo
  Bekkers et al\[[@B121]\]   2010       90        T2w-TSE              Acute MSI and LVEF increase at follow-up lowest if IMH present. But IMH no prognostic significance beyond MVO in predicting LVEF   5 d                    103 d
  O'Regan et al\[[@B126]\]   2010       50        T2\*                 IMH presence univariate predictor of LVEF and LV volumes. However only IS independently predicted LVEF                             3 d                    N/A
  Ganame et al\[[@B25]\]     2009       98        T2w-TSE              IMH extent strongest IP of LVR in model with IS, E-MVO, Troponin-I, AAR, TTR, IS                                                   2 d                    4 mo

IS: Infarct size; IP: Independent predictor; LVR: Left ventricular remodelling; MVO: Microvascular obstruction; LVEF: Left ventricular ejection fraction; LVESVI: Left-ventricular end systolic volume index; T2w-TSE: T2-weighted turbo spin-echo; AAR: Area at risk; MSI: Myocardial salvage index; N/A: Not applicable.

Prognostic importance of CMR IMH in AMI
---------------------------------------

Multivariate analyses including IMH as a prognostic indicator also show mixed results. Amabile et al\[[@B133]\] demonstrated that IMH on T2w-TSE at 4 d post STEMI was the strongest independent predictor of MACE at 1-year (HR 2.8) in a model including LVEF, ST-resolution and L-MVO. Husser et al\[[@B33]\] showed that only LVEF and IMH extent on T2w-TSE independently predicted MACE at 140 wk follow-up in a model containing LV volumes, AAR, IS and L-MVO. However IMH and MVO extent showed strong correlation (r = 0.95) and adding T2w imaging to a model containing LGE and cine imaging did not improve the predictive power for MACE, supporting a strong concordance of IMH and MVO. Eitel et al\[[@B125]\] demonstrated that IMH presence on T2w-TSE and LVEF \< 53% were the only CMR independent predictors of MACE at 6 mo in a model with lone MVO. Carrick et al\[[@B74]\] recently demonstrated that IMH on T2\* mapping was the strongest independent predictor of cardiac death and heart failure hospitalisation at 830 d follow-up. In their multivariate model, L-MVO was not a predictor suggesting that IMH reflects extreme microvascular injury.

ISCHAEMIC AAR AND MYOCARDIAL SALVAGE IN AMI
===========================================

Background
----------

Oedema is seen in acute cardiac inflammation. In STEMI, it signifies reversible myocardial injury in the ischaemic cascade. The area of oedematous myocardium defines the ischaemic AAR supplied by the occluded IRA\[[@B61],[@B134]\].

CMR assessment of AAR and MSI in AMI
------------------------------------

The T2 (transverse) relaxation time is increased by regional water content\[[@B135]\]. T2w-TSE sequences illustrate oedema as hyperintensity\[[@B134]\] and are currently the mainstay of CMR oedema imaging. Most commonly used is the black-blood T2-weighted short-tau inversion-recovery sequence (T2w-STIR). This uses two initial inversion pulses to null moving blood. This is followed by a third inversion pulse, which nulls tissues with short T1 times (fat) to provide high contrast between blood (nulled) and myocardium\[[@B134],[@B136]\]. T2w imaging of myocardial oedema is well-validated in animal studies assessing myocardial water volume on histological assessment\[[@B137]\] and fluorescent microspheres\[[@B77]\]. T2w oedema assessment is well-validated with SPECT\[[@B138]-[@B140]\] and angiographic markers of AAR (BARI\[[@B141]\], APPROACHp\[[@B142]\] scoring). AAR on T2w can be assessed accurately for upto 1-wk post-PPCI unlike SPECT, which requires radionucleotide administration during coronary occlusion and has higher spatial resolution and thus ability to detect subendocardial injury\[[@B138]\].

However T2w-TSE imaging has inherent disadvantages that can compromise image quality and oedema detection. Upto 30% of datasets are non-analysable in studies\[[@B24],[@B143],[@B144]\]. New T2w sequences have been studied, with encouraging results (Figure [7](#F7){ref-type="fig"}).

![Alternative sequences to dark-blood T2-weighted turbo spin-echo for visualising oedema. Left: Inherent disadvantages of T2w-TSE\[[@B134],[@B144]-[@B147]\]; Right: Sequences compared with T2w-TSE: (1)\[[@B145]\], (2)\[[@B141],[@B142],[@B144],[@B148]\], (3)\[[@B149],[@B150]\], (4)\[[@B144]\], (5)\[[@B151],[@B152]\], (6)\[[@B153],[@B154]\], (7)\[[@B155]\]. T2w-TSE: T2-weighted turbo spin-echo; DWI: Diffusion-weighted imaging; AAR: Area at risk.](WJC-9-109-g007){#F7}

The aim of prompt reperfusion is to limit IS by minimizing the conversion of reversibly injured myocardial cells (AAR) into necrotic, infarcted tissue (IS)\[[@B95],[@B156]\]. Anterior STEMI typically results in larger IS due to the larger coronary bed supplied by the left anterior descending artery\[[@B14],[@B80],[@B82]\]. Hence a more accurate assessment of revascularisation strategies can be provided by adjusting IS for the AAR. The resulting myocardial salvage index (MSI) defines the proportion of reversibly injured tissue (AAR) that does not progress to infarction (IS, Equation 1, Figure [8](#F8){ref-type="fig"}). MSI is expressed as percentage of the initial AAR \[0% is no salvage, 100% is complete salvage (aborted STEMI)\]\[[@B157]\].

![Calculation of salvaged myocardium. A: SSFP end-diastolic cine image; B: SSFP end-systolic cine image showing hypokinetic basal anterolateral segment (\*); C: T2w-STIR image showing oedema (AAR) in anterolateral wall consistent with circumflex artery occlusion; D: Corresponding LGE image with near-transmural infarction; E: Calculation of salvaged myocardium in blue. SSFP: Steady-state free precession; T2w-STIR: T2-weighted short-tau inversion-recovery sequence; LGE: Late gadolinium enhancement.](WJC-9-109-g008){#F8}

Equation 1: Myocardial salvage index (MSI, %) = 100 × \[(AAR-IS)/(AAR)\].

Desch showed excellent intraobserver and interobserver agreement for MSI assessment using T2w-STIR and LGE (coefficients of variation approximately 5.0%) and excellent test-retest reproducibility in a study of 20 acute STEMI patients\[[@B158]\].

Other determinants of AAR include TTR\[[@B91],[@B130],[@B159]-[@B162]\], extent of collateralised IRA territory flow\[[@B5],[@B80],[@B159],[@B163]\], TIMI-flow pre PPCI, LAD IRA and diabetes\[[@B91]\].

Studies of the chronology of oedema suggest that it occurs very early in the ischaemic cascade. Abdel-Aty confirmed the presence of transmural oedema in canines on *in-vivo* T2w imaging at 28 min post LAD occlusion at which point LGE and troponin release were absent, indicating reversible injury\[[@B164]\]. Fernández-Jiménez et al\[[@B165]\] however recently demonstrated a bimodal pattern of AAR extent in pigs with T2-mapping CMR and histological water quantification. They showed peak values at 2 h thought to be a direct result of reperfusion, followed by a return to baseline at 2 d and then progressive increase towards peak values at 7 d, with the latter peak felt due to water replacement of cleared cellular debris. Studies of temporal changes in AAR and MSI in humans are summarised in Table [12](#T12){ref-type="table"}. Correct timing of oedema imaging is crucial in accurate calculation of AAR and MSI.

###### 

Temporal changes in cardiovascular magnetic resonance-derived area at risk and myocardial salvage index in acute myocardial infarction

  **Ref**.                        **Year**   ***n***   **CMR timepoints post STEMI**   **AAR, IS method**          **Main findings**
  ------------------------------- ---------- --------- ------------------------------- --------------------------- ----------------------------------------------------------------------------------------------------------------------------
  Mather et al\[[@B18]\]          2011       48        2 d → 1 wk → 30 d → 3 mo        \> 2SD STIR, \> 2SD LGE     AAR reduction at successive timepoints, 1-3 mo (-75%). No change MSI at d2 or 1 wk as IS and AAR decreased proportionally
  Dall'Armelina et al\[[@B21]\]   2011       30        2 d → 1 wk → 2 wk → 6 mo        \> 2SD T2p-BB, \> 2SD LGE   100% had oedema at d2. AAR stable over 1st week (37% *vs* 39% LVM). Decreased by 2 wk and nearly resolved at 6 mo
  Carlsson et al\[[@B138]\]       2009       16        1 d → 1 wk → 6 wk → 6 mo        Manual STIR, and LGE        AAR at all timepoints. AAR stable in 1st week, correlated with 1 wk SPECT. Decrease by 1 mo (10% LVM), nearly gone by 6 mo
  Ripa et al\[[@B5]\]             2007       58        2 d → 1 mo → 6 mo               Manual STIR and LGE         All had oedema at d2. AAR decreased at all time points. No data on MSI in this study

AAR: Area at risk; MSI: Myocardial salvage index; AAR, LGE method: SD: Standard deviations; STIR: T2-weighted short-tau inversion recovery imaging; T2p-SS-BB: T2-prepared single-shot bright-blood; 3T: 3.0 tesla field strength; IS: Infarct size.

The near-resolution of oedema by 6 mo\[[@B5],[@B18],[@B21],[@B91],[@B138]\] allows distinction between acute and chronic infarcts when combined with LGE imaging.

CMR MSI as a predictor of LV function and remodelling in AMI
------------------------------------------------------------

Myocardial salvage is a strong univariate predictor of medium-term LV function\[[@B14],[@B166],[@B167]\] and adverse LV remodelling post STEMI\[[@B14],[@B27],[@B91],[@B161]\]. Multivariate analysis demonstrates mixed results. MSI independently predicted LV remodelling in the work of Mather\[[@B131]\] (Table [13](#T13){ref-type="table"}). However MSI was not a predictor once IS was added into multivariate models in studies by Monmeneu\[[@B91]\] and Masci\[[@B14]\]. This, in conjunction with the correlation between MSI and IS, and AAR and IS\[[@B26]\] questions whether MSI and IS are truly independent of each other in predicting LV remodelling and prognosis post STEMI. It could be argued that since MSI adjusts IS for the extent of AAR, it may have less inherent variability than IS. Since up to 30% of AAR datasets have been deemed non-diagnostic in previous studies\[[@B24],[@B143],[@B144]\], this may impact on the robustness of MSI quantification whereas IS datasets are exceptionally rarely excluded based on image quality. It is not clear currently whether IS or MSI is the better measure of revascularisation success post PPCI.

###### 

Cardiovascular magnetic resonance studies showing the importance of myocardial salvage index on left ventricular function and remodelling in acute myocardial infarction

  **Ref**.                   **Year**   ***n***   **AAR, IS method**        **Main findings**                                                                                                     **CMR timepoint post STEMI**   **Follow-up**
  -------------------------- ---------- --------- ------------------------- --------------------------------------------------------------------------------------------------------------------- ------------------------------ ---------------
  Mather et al\[[@B131]\]    2011       48        \> 2SD STIR, \> 2SD LGE   MSI was IP for LVR (OR 0.95) in model including LV volumes, LVEF, IS, IMH, MVO                                        2 d                            3 mo
  Monmeneu et al\[[@B91]\]   2012       118       \> 2SD STIR, \> 2SD LGE   MSI univariate predictor of LVR and final LVEF. However not IP of LVR in model with LVESVI, IS, no. transmural segs   6 d                            6 mo
  Masci et al\[[@B14]\]      2011       260       \> 2SD STIR, \> 5SD LGE   MSI strong univariate predictor of LVR and final LVEF. However not IP in model including IS, MVO                      1 wk                           4 mo
  Masci et al\[[@B26]\]      2010       137       \> 2SD STIR, \> 5SD LGE   MSI strongest IP for LVR However IS and MSI (r = -0.72) and IS and AAR (r = 0.85) correlated                          1 wk                           4 mo

IS: Infarct size; IP: Independent predictor; LVR: Left ventricular remodelling; MVO: Microvascular obstruction; LVEF: Left ventricular ejection fraction; LVESVI: Left-ventricular end systolic volume index; STIR: T2-weighted short-tau inversion-recovery; LGE: Late gadolinium enhancement.

Prognostic importance of CMR MSI in AMI
---------------------------------------

Historically, the prognostic value of MSI was demonstrated using SPECT. Ndrepapa first showed that MSI was the strongest independent predictor of 6-mo mortality\[[@B168]\]. MSI was an independent prognostic indicator in the medium term post STEMI in two studies. Although both studies were from the same patient cohort, they have both been included in Table [14](#T14){ref-type="table"} due to their differing primary findings.

###### 

Cardiovascular magnetic resonance studies illustrating the prognostic importance of myocardial salvage index in acute myocardial infarction

  **Ref**.                 **Year**   ***n***   **AAR, IS method**         **Main findings**                                                                                                                                                   **CMR timepoint post STEMI**   **Follow-up**
  ------------------------ ---------- --------- -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------ ---------------
  Eitel et al\[[@B34]\]    2011       208       \> 2SD -STIR, \> 5SD LGE   MSI was only CMR-based IP of mortality in model with age, IS, MVO, LVEF, TIMI- post PPCI, diabetes, age (IS not IP). MSI not IP of MACE (only IS, LVEF, age were)   3 d                            19 mo
  Eitel et al\[[@B161]\]   2010       208       \> 2SD STIR, \> 5SD LGE    MSI was only IP for MACE and mortality in model including LVEF, MVO, IS, ST-resolution and TIMI-grade post PCI                                                      3 d                            6 mo

IS: Infarct size; PCI: Percutaneous coronary intervention; MACE: Major adverse cardiovascular events; IP: Independent predictor; MVO: Microvascular obstruction; LVEF: Left ventricular ejection fraction.

T1, T2 AND T2\* QUANTIFICATION AND MAPPING IN AMI
=================================================

The current mainstay of LGE and T2w techniques for the detection of infarct and oedema rely on semi-quantitative threshold-based quantification methods using arbitrary SI cut-offs compared to user-defined regions of interest, automated algorithms or are based on manual planimetry. There is currently no consensus on the optimal quantification method for IS or AAR using these sequences. This can lead to subjectivity and dependence upon optimal nulling of normal myocardium and thus potential for error. In addition, commonly used T2w-TSE sequences suffer from non-diagnostic image quality in upto 30% of patients\[[@B24],[@B143],[@B144]\].

T1, T2 and T2\* quantification present an exciting and complementary approach to LGE and T2w imaging. Developed by Messroghli et al\[[@B169]\] in 2003, their use in MI research has accelerated over the last 5 years. They allow not only the location and extent of infarction, oedema, MVO and IMH to be determined from subsequent parametric myocardial maps, but also the severity of these pathologies to be assessed through the magnitude of values obtained\[[@B170],[@B171]\]. These methods are not reliant on reference regions of interest and do not suffer from T2w-TSE artefacts.

T1 mapping (longitudinal relaxation)
------------------------------------

T1 relaxation curves allow calculation of the T1 time (time taken for recovery of 63% of longitudinal magnetization). The currently used curve-fitting sequences used include MOLLI (Modified Look-Locker Inversion Recovery), ShMOLLI (Shortened MOLLI), SASHA (SAturation recovery single-SHot Acquisition) and SAPPHIRE (SAturation Pulse Prepared Heart rate independent Inversion REcovery)\[[@B172]\]. Infarcted and oedematous myocardium demonstrate prolonged pre-contrast T1 values and reduced post-contrast T1 values compared with normal myocardium, allowing infarct visualisation and quantification\[[@B169],[@B170],[@B173],[@B174]\]. Messroghli showed that this technique had high test-retest reproducibility\[[@B175]\], was stable within the range of heart rates commonly seen in clinical practice and showed comparable sensitivity for IS quantification compared with LGE\[[@B169],[@B173],[@B176]\]. T1 values within in the infarct core were recently shown to demonstrate a strong inverse correlation with L-MVO extent, incidence of LV remodelling and all-cause mortality at 2.5 years\[[@B177]\].

T2 mapping (transverse relaxation)
----------------------------------

T2w images are generated using a T2-SSFP sequence with log-transformed curve-fitting T2 quantification, with different T2 preparation (TE) times. T2 mapping has shown excellent reproducibility and no effect of slow-flow, through-plane movement, SI loss, or effects of coil SI inhomogeneities\[[@B151],[@B178]\]. T2 mapping accurately assessed oedema in 96% of patients (good image quality in 100%), whereas T2w-STIR detected oedema in only 67% of patients (15% non-diagnostic 15%)\[[@B151]\]. High observer agreement and close agreement between T1 (r^2^ = 0.94) and T2 maps (r^2^ = 0.96), and fluorescent microspheres for AAR detection was seen in canine myocardium\[[@B179]\].

T2\* mapping (transverse relaxation in presence of field inhomogeneities)
-------------------------------------------------------------------------

T2\* mapping allows visualisation and quantification of IMH due to the presence of paramagnetic haemoglobin breakdown products. A cut-off value of \< 20 ms has been used to define the presence of IMH\[[@B180]\]. Although the evidence base for T2\* mapping in assessing IMH is currently limited, O'Regan demonstrated that it has greater sensitivity than T2w-STIR imaging (100% *vs* 90%) for IMH. Kali showed good correlation between *in-vivo* T2\* and histological assessment of IMH and iron levels in canine myocardium\[[@B127],[@B128]\]. T2\* mapping may improve the specificity of IMH detected on CMR\[[@B131]\].

T1, T2 and T2\* surrogate markers hold promise for improving the accuracy of detection of infarct, oedema and IMH respectively, and further improving statistical power of STEMI studies. However, due to the importance of protocol standardisation, these techniques are rarely used in multicentre studies at present.

RIGHT VENTRICULAR INVOLVEMENT IN AMI
====================================

CMR assessment of right ventricular infarction in AMI
-----------------------------------------------------

CMR is the gold standard imaging modality for the assessment of right ventricular (RV) volumes, function, oedema\[[@B181]\] and infarction (RVI)\[[@B182]\]. CMR identifies RVI with greater sensitivity than echocardiography, ECG (V4~R~ ST-segment elevation) and clinical examination\[[@B183],[@B184]\] and demonstrates RV L-MVO\[[@B185],[@B186]\]. There is good interobserver and intraobserver agreement for the identification of RV oedema (κ = 0.62, κ = 0.62, respectively) and very good agreement for RVI (κ = 0.70, κ = 0.70, respectively)\[[@B181]\]. The high MSI in RVI often \> 90%\[[@B187],[@B188]\] is thought to be due the relatively low RV nutrient needs, direct endocardial oxygen diffusion and good collateral blood supply\[[@B188],[@B189]\].

Prognostic importance of CMR-derived right ventricular infarction in AMI
------------------------------------------------------------------------

RVI confers adverse short-term prognosis, with a large meta-analysis (*n* = 7136) demonstrating that RVI on ECG, echocardiography or radionucleotide imaging predicted 30-d mortality and in-hospital MACE\[[@B190]\]. Shah demonstrated the prognostic importance of right ventricular infarction on imaging, where RVEF \< 38% on radionucleotide ventriculography post STEMI was a strong independent predictor of 1-year mortality\[[@B191]\]. Right ventricular infarction is a strong independent predictor of medium to long-term prognosis in a small number of CMR studies (Table [15](#T15){ref-type="table"}).

###### 

Cardiovascular magnetic resonance studies illustrating the prognostic importance of right ventricular infarction in acute myocardial infarction

  **Ref**.                          **Year**   ***n***   **RV LGE analysis method**   **Main findings**                                         **CMR timepoint post STEMI**   **Follow-up**
  --------------------------------- ---------- --------- ---------------------------- --------------------------------------------------------- ------------------------------ ---------------
  Jensen et al\[[@B184]\]           2010       50        Manual                       RVI only IP of MACE in model with age, sex, LVEF, LV IS   3 d                            32 mo
  Miszalski-Jamka et al\[[@B98]\]   2010       99        Manual                       RVEF (HR 1.46) and RVI extent (HR 1.50) IP for MACE       "3-5 d"                        1150 d
  Grothoff et al\[[@B187]\]         2012       450       Manual                       RVI was IP of MACE (HR 6.70)                              "1-4 d"                        20 mo

MACE: Major adverse cardiovascular events; IP: Independent predictor; HR: Hazard ratio; RV: Right ventricle; LVEF: Left ventricular ejection fraction; LGE: Late gadolinium enhancement; IS: Infarct size; RVI: Right ventricular infarction.

WHEN IS THE OPTIMAL TIME TO PERFORM CMR ASSESSMENT IN MI?
=========================================================

In acute STEMI, IS, AAR and MSI are best imaged at 7 d post PPCI due to overestimation of necrosis on LGE, and IS at 7 d best predicts final IS, LV remodelling and function and prognosis\[[@B5]-[@B7],[@B9],[@B18],[@B20],[@B21]\]. Human studies suggest that AAR is stable during the first week\[[@B21],[@B138]\]. Although Fernández-Jiménez et al\[[@B165]\] demonstrated a bimodal AAR peak in pigs, their drop in AAR extent on T2w CMR at 2 d post-reperfusion may be due to a high incidence of IMH in pigs and peak IMH extent at 2 d\[[@B74]\]. Indeed the drop in AAR extent on the gold standard of histological water analysis in their study at 2 d was much less pronounced, and at 7 d AAR extent had returned to stable peak levels. In addition, studies demonstrating close agreement between T2w-derived AAR and the reference non-invasive modality of SPECT\[[@B138],[@B139]\] were undertaken at 7 d post STEMI. MVO and IMH extent peak at 48 h then decrease\[[@B18]\] but are present at 7 d\[[@B9],[@B18]\]. Although undertaking CMR at 7-d may potentially underestimate MVO and IMH extent\[[@B9],[@B18],[@B74]\], this may be minimised by expressing MVO and IMH extent as a proportion of IS rather than LV mass, to correct for the corresponding reduction in IS. Thus, acutely post STEMI for the assessment of IS, MSI, MVO and IMH, imaging at 7 d may provide the best compromise in relation to their temporal changes\[[@B5]-[@B7],[@B9],[@B18],[@B20],[@B21]\] for accurate quantification and prediction of LV function, remodelling and prognosis. This needs to be balanced with contemporary clinical practice where patients are typically discharged at 3-4 d post-PPCI, and the risk of early attrition. Using final IS at follow-up as a primary outcome risks underestimating potential differences in treatment strategies due to greater infarct resorption with the larger infarcts.

Data on the chronology of IS suggests that infarct resorption is essentially complete by 3 mo post MI\[[@B9],[@B18],[@B20],[@B74]\]. However a key objective of follow-up CMR is to assess LV geometry and remodelling and hence must allow the relatively slower adaptations of ventricular volumes (approximately 12 mo), compared with changes in IS and LVEF to complete. LVEF shows no significant change after 1-mo post STEMI. Follow-up CMR at 3 and 6-mo may fail to provide an accurate assessment of LV volumes and remodelling. The evidence base suggests that in order to allow completion of the trio of IS, LVEF *and* LV volumetric changes, follow-up CMR should be performed at 12-mo post STEMI\[[@B5],[@B7],[@B18],[@B20],[@B21]\]. When correlating CMR and clinical outcomes, the longer timepoint of 12-mo also permits more reliable clinical follow-up.

Standardisation of LGE, AAR and IMH sequences and quantification methods is equally important in light of newer T1, T2 and T2\*-mapping sequences and inherent image quality issues associated with T2w-TSE.

CONCLUSION
==========

Contrast-enhanced CMR offers robust, validated and reproducible surrogate markers, providing an accurate representation of pathophysiology, assessment of myocardial function and injury, and predictive value for medium to long-term LV function, remodelling and prognosis following PPCI for STEMI. Tables [16](#T16){ref-type="table"} and [17](#T17){ref-type="table"} summarise the key prospective studies illustrating the independent predictive value of CMR markers for LV remodelling (studies where *n* \> 100, follow-up CMR ≥ 3 mo post PPCI) and prognosis (studies where *n* \> 100, ≥ 6 mo follow-up) respectively.

###### 

Key studies illustrating the independent predictive value of cardiovascular magnetic resonance markers for left ventricular remodelling

  **CMR marker**   **Ref**.                   **Year**   ***n***   **CMR quantification**      **Main findings**                                                              **Acute CMR time**   **Follow-up CMR time**
  ---------------- -------------------------- ---------- --------- --------------------------- ------------------------------------------------------------------------------ -------------------- ------------------------
  IS               Husser et al\[[@B33]\]     2012       304       2SD                         IS extent IP for LVR in model with LVEF, IS, LV volumes, MVO                   6 d                  189 d
  IS               Monmeneu et al\[[@B91]\]   2012       118       2SD                         Number of segments \> 50% transmurality IP for LVR                             6 d                  6 mo
  IS               Wu et al\[[@B94]\]         2008       122       Manual                      IS extent at 2 d only IP for LVEF and LVR                                      2 d                  4 mo
  IS               Hombach et al\[[@B6]\]     2005       110       Manual                      IS extent at 6 d was an IP for LVR in model with MVO, % transmurality          6 d                  225 d
  L-MVO            Weir et al\[[@B112]\]      2010       100       Manual                      L-MVO extent was only IP of LVR in model with TIMI post PCI, E-MVO, IS         4 d                  6 mo
  L-MVO            Hombach et al\[[@B6]\]     2005       110       Manual                      L-MVO extent IP of LVR in model with baseline IS, infarct transmurality        6 d                  225 d
  IMH              Carrick et al\[[@B74]\]    2016       245       T2\*                        IMH strongest IP of LVR in model with patient/angio characteristics, LVEDVI    3 d                  7 mo
  IMH              Husser et al\[[@B33]\]     2012       304       T2w-TSE                     IMH strongest IP for LVR in model with LVEF, IS, LV volumes, L-MVO             6 d                  189 d
  MSI              Monmeneu et al\[[@B91]\]   2012       118       2SD LGR/STIR                MSI univariate but not IP of LVR in model with IS, LVESVI, segments \> 50%     6 d                  6 mo
  MSI              Masci et al\[[@B14]\]      2011       260       2SD STIR, 5SD LGE           MSI univariate predictor of LVR and final LVEF. However not IP of either       1 wk                 4 mo
  MSI              Masci et al\[[@B26]\]      2010       137       \> SD STIR, 5SD LGE         MSI strongest IP for LVR. However IS and MSI and IS and AAR correlated         1 wk                 4 mo
  T1               Carrick et al\[[@B177]\]   2016       300       T1 map, 2SD STIR, 5SD LGE   Infarct core native T1 inverse relationship with LVR (OR 0.91 per -10 ms T1)   2 d                  6 mo

Criteria: Individual studies with *n* ≥ 100 and follow-up CMR ≥ 3 mo post-PPCI. IS: Infarct size; L-MVO: Late microvascular obstruction; IMH: Intramyocardial haemorrhage; MSI: Myocardial salvage index; SD: Standard deviations; STIR: T2-weighted short-tau inversion recovery; LGE: Late gadolinium enhancement; IP: Independent predictor; LV: Left ventricular; LVEF: Left ventricular ejection fraction; AAR: Area at risk; LVEDVI: Left ventricular end-diastolic volume; CMR: Cardiovascular magnetic resonance.

###### 

Key studies illustrating the independent predictive value of cardiovascular magnetic resonance markers for prognosis

  **CMR marker**   **Ref**.                    **Year**   ***n***   **CMR quantification**        **Main findings**                                                                                                                                                **Acute CMR time**   **Follow-up**
  ---------------- --------------------------- ---------- --------- ----------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- ---------------
  IS               Husser et al\[[@B96]\]      2013       250       \> 2SD                        Extent of transmural infarction was only IP for MACE                                                                                                             7 d                  163 wk
  IS               Izquierdo et al\[[@B97]\]   2013       440       \> 2SD                        IS was IP for arrhythmic cardiac events in model including LVEF, hypertension                                                                                    7 d                  123 wk
  IS               Eitel et al\[[@B34]\]       2011       208       \> 5SD                        IS was IP of MACE in model with MVO, LVEF, MSI, Killip, TIMI flow post-PPCI                                                                                      3 d                  18.5 mo
  IS               Larose et al\[[@B67]\]      2010       103       FWHM                          IS strongest IP for MACE in model with LVEF, CK. LGE \> 23% for MACE                                                                                             4.5 h                2 yr
  IS               Bodi et al\[[@B38]\]        2009       214       \> 2SD                        Extent of transmural infarction (no. of segments \> 50% transmurality) IP for MACE                                                                               7 d                  553 d
  IS               Wu et al\[[@B99]\]          2008       122       Manual                        IS only IP of 2 yr MACE in model containing LVEF, LVESVI (HR 1.06)                                                                                               2 d                  538 d
  L-MVO            Regenfus et al\[[@B117]\]   2015       249       Manual                        MVO extent strongest IP for MACE in model with IS, LVEF, TIMI and no. vessels                                                                                    3.7 d                72 mo
  L-MVO            Eitel et al\[[@B119]\]      2014       738       \> 5SD                        L-MVO \> 1.4% LVM IP of MACE in model with LVEDVI, LVEF, clinical markers                                                                                        7 d                  6 mo
  L-MVO            de Waha et al\[[@B120]\]    2012       438       Manual                        L-MVO extent IP for MACE in model with IS, LV volumes. L-MVO/IS strongest IP                                                                                     3 d                  19 mo
  L-MVO            de Waha et al\[[@B36]\]     2010       438       Manual                        L-MVO strongest IP of MACE/mortality in model with IS, LVEF, STR, TIMI post                                                                                      3 d                  19 mo
  L-MVO            Cochet et al\[[@B37]\]      2009       184       Manual                        L-MVO strongest IP for MACE in model with GRACE, IS, LVEF. E-MVO weaker IP                                                                                       "3-7 d"              12 mo
  L-MVO            Bruder et al\[[@B116]\]     2008       143       Manual                        L-MVO extent \> 0.5% LV mass IP for MACE in model with IS, LVEF, age, DM, sex                                                                                    4.5 d                12 mo
  L-MVO            Hombach et al\[[@B6]\]      2005       110       Manual                        L-MVO IP for MACE (*P* = 0.04) in model with LV end-diastolic volume and LVEF                                                                                    6 d                  268 d
  IMH              Carrick et al\[[@B74]\]     2016       245       T2\*                          IMH strongest IP of CV death and HF. Multivariate model, L-MVO not predictor                                                                                     3 d                  830 d
  IMH              Amabile et al\[[@B133]\]    2012       114       T2w-TSE                       IMH presence was strongest predictor of MACE in model with MVO, LVEF, STR                                                                                        4 d                  12 mo
  IMH              Husser et al\[[@B33]\]      2012       304       T2w-TSE                       IMH IP for MACE in model with AAR, IS, L-MVO. T2w. No inc. value with LGE                                                                                        6 d                  140 wk
  IMH              Eitel et al\[[@B125]\]      2011       346       T2w-TSE                       IMH IP of MACE in model with L-MVO. T2w inc. value with LGE and cine                                                                                             3 d                  6 mo
  MSI              Eitel et al\[[@B34]\]       2011       208       \> 2SD/\> 5SD                 MSI only CMR IP of mortality in model with age, IS, MVO, LVEF, TIMI post, IS                                                                                     3 d                  19 mo
  MSI              Eitel et al\[[@B161]\]      2010       208       \> 2SD/\> 5SD                 MSI only IP for MACE/mortality in model with LVEF, MVO, IS, STR, TIMI post                                                                                       3 d                  6 mo
  T1               Carrick et al\[[@B177]\]    2016       300       T1 map, \> 2SD STIR, \> 5SD   Infarct core T1 inverse association with risk of mortality and heart failure hospitalisation, in model with LVEF, infarct T2, IMH. Similar prognostic as L-MVO   2 d                  2.5 yr

Criteria: Individual studies with *n* ≥ 100 and follow-up CMR ≥ 6 mo follow-up. IS: Infarct size; L-MVO: Late microvascular obstruction; IMH: Intramyocardial haemorrhage; MSI: Myocardial salvage index; SD: Standard deviations; STIR: T2-weighted short-tau inversion recovery; LGE: Late gadolinium enhancement; IP: Independent predictor; LV: Left ventricular; LVEF: Left ventricular ejection fraction; AAR: Area at risk; LVEDVI: Left ventricular end-diastolic volume; CK: Creatine kinase; T2w-TSE: T2-weighted turbo spin echo; MACE: Major adverse cardiovascular events; CV: Cardiovascular.

In the acute phase, CMR can be performed accurately for up to 7 d post PPCI. CMR delivers no radiation to the patient and this makes it ideal for serial studies. The multimodal nature of CMR allows a multiparametric study of cardiac function, structure and volumes within a single study, which can be undertaken within approximately 45 min in the majority of patients. It is likely that CMR will become the mainstay of cardiac imaging, providing an important role in risk stratification and treatment post STEMI. Focus needs to be continued in translating findings on the prognostic importance of surrogate markers to development of therapeutic targets post STEMI.
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